Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the National Health Act 1953, section 100 for patients with relapsed or refractory Hodgkin lymphoma, and for patients with Stage III or IV CD30 positive Hodgkin lymphoma.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing brentuximab vedotin.
Section 100 arrangements
This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:
- an approved private hospital
- a public participating hospital.
This item isn't PBS-subsidised for public hospital in-patients.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised brentuximab vedotin to treat relapsed or refractory Hodgkin lymphoma, or Stage III or IV CD30 positive Hodgkin lymphoma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised brentuximab vedotin to treat relapsed or refractory Hodgkin lymphoma, or Stage III or IV CD30 positive Hodgkin lymphoma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.